Roivant Sciences Ltd.

The momentum for this stock is not very good. Roivant Sciences Ltd. is not a good value stock. Roivant Sciences Ltd. is not a good growth stock. Roivant Sciences Ltd. is not very popular among insiders. Roivant Sciences Ltd. is a mediocre stock to choose.
Log in to see more information.

News

United Services Automobile Association Takes $284,000 Position in Roivant Sciences Ltd. (NASDAQ:ROIV)
United Services Automobile Association Takes $284,000 Position in Roivant Sciences Ltd. (NASDAQ:ROIV)

Zolmax United Services Automobile Association purchased a new position in shares of Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) during the second quarter, according to its most recent filing with the...\n more…

4 Analysts Assess Roivant Sciences: What You Need To Know
4 Analysts Assess Roivant Sciences: What You Need To Know

Benzinga In the preceding three months, 4 analysts have released ratings for Roivant Sciences ROIV, presenting a wide array of perspectives from bullish to bearish. The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.\n more…

Roivant Sciences price target raised by 50c at BofA, here's why
Roivant Sciences price target raised by 50c at BofA, here's why

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

Natixis Advisors LLC Purchases 15,280 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV)
Natixis Advisors LLC Purchases 15,280 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV)

Ticker Report Natixis Advisors LLC increased its holdings in Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 12.1% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund...\n more…

Does Montes Archimedes Acquisition (ROIV) Have the Potential to Rally 35.12% as Wall Street Analysts Expect?
Does Montes Archimedes Acquisition (ROIV) Have the Potential to Rally 35.12% as Wall Street Analysts Expect?

Zacks Investment Research Roivant Sciences Ltd. (ROIV) closed the last trading session at $12.50, gaining 11.8% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set...\n more…

Roivant Sciences' mosliciguat shows efficacy in pulmonary hypertension trial
Roivant Sciences' mosliciguat shows efficacy in pulmonary hypertension trial

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…